Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 2 Interventional Results available

Study to Assess the Efficacy and Safety of Budesonide (PT008) in Adult Subjects With Mild to Moderate Persistent Asthma

ClinicalTrials.gov ID: NCT02105012

Public ClinicalTrials.gov record NCT02105012. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Randomized, Double-Blind, Chronic Dosing (4 Weeks), Four-Period, Five-Treatment, Incomplete Block, Cross-Over, Multi-Center Study to Assess the Efficacy and Safety of Four Doses of Budesonide Inhalation Aerosol (BD MDI, PT008) Relative to Placebo MDI in Adult Subjects With Mild to Moderate Persistent Asthma

Study identification

NCT ID
NCT02105012
Recruitment status
Completed
Study type
Interventional
Phase
Phase 2
Lead sponsor
Pearl Therapeutics, Inc.
Industry
Enrollment
147 participants

Conditions and interventions

Conditions

Interventions

  • BD MDI 320 µg Drug
  • BD MDI 160 µg Drug
  • BD MDI 80 µg Drug
  • BD MDI 40 µg Drug
  • Placebo MDI Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 65 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 31, 2014
Primary completion
Aug 31, 2015
Completion
Sep 3, 2015
Last update posted
Jun 5, 2017

2014 – 2015

United States locations

U.S. sites
41
U.S. states
16
U.S. cities
40
Facility City State ZIP Site status
Pearl Therapeutics Study Site Athens Alabama
Pearl Therapeutics Study Site Birmingham Alabama
Pearl Therapeutics Study Site Foley Alabama
Pearl Therapeutics Study Site Los Angeles California
Pearl Therapeutics Los Angeles California
Pearl Therapeutics Study Site Rolling Hills Estates California
Pearl Therapeutics Study Site San Diego California
Pearl Therapeutics Study Site Stockton California
Pearl Therapeutics Study Site Clearwater Florida
Pearl Therapeutics Study Site Clermont Florida
Pearl Therapeutics Study Site Miami Florida
Pearl Therapeutics Study Site Orlando Florida
Pearl Therapeutics Study Site Ormond Beach Florida
Pearl Therapeutics Study Site Saint Cloud Florida
Pearl Therapeutics Study Site Sebring Florida
Pearl Therapeutics Study Site Tampa Florida
Pearl Therapeutics Study Site Blue Island Illinois
Pearl Therapeutics Study Site North Dartmouth Massachusetts
Pearl Therapeutics Study Site Hazelwood Missouri
Pearl Therapeutics Study Site Skillman New Jersey
Pearl Therapeutics Study Site Charlotte North Carolina
Pearl Therapeutics Study Site Winston-Salem North Carolina
Pearl Therapeutics Study Site Cincinnati Ohio
Pearl Therapeutics Study Site Columbus Ohio
Pearl Therapeutics Study Site Dayton Ohio
Pearl Therapeutics Study Site Middleburg Heights Ohio
Pearl Therapeutics Study Site Oregon Ohio
Pearl Therapeutics Study Site Sylvania Ohio
Pearl Therapeutics Study Site Toledo Ohio
Pearl Therapeutics Study Site Oklahoma City Oklahoma
Pearl Therapeutics Study Site Lake Oswego Oregon
Pearl Therapeutics Study Site Medford Oregon
Pearl Therapeutics Study Site Greenville South Carolina
Pearl Therapeutics Study Site Spartanburg South Carolina
Pearl Therapeutics Study Site Rapid City South Dakota
Pearl Therapeutics Study Site Tullahoma Tennessee
Pearl Therapeutics Study Site El Paso Texas
Pearl Therapeutics Study Site Houston Texas
Pearl Therapeutics Study Site Plano Texas
Pearl Therapeutics Study Site San Antonio Texas
Pearl Therapeutics Study Site Everett Washington

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT02105012, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jun 5, 2017 · Synced Jul 22, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT02105012 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →